Levosimendan Waymade

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Waymade (Levosimendan)

Q: What is Levosimendan Waymade used for?

Levosimendan Waymade is indicated for the intravenous treatment of acute decompensated heart failure. It helps improve cardiac contractility and supports hemodynamic stability in patients who require rapid inotropic support, typically in intensive care or cardiac unit settings.

Q: How does Levosimendan work?

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractile force without increasing intracellular calcium levels. At the same time it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, thereby improving overall cardiac output.

Q: What is the usual dose of Levosimendan Waymade?

The dosing regimen for Levosimendan Waymade is determined by the prescribing physician based on the patient’s clinical condition, weight, and response. Healthcare professionals set the infusion rate and duration according to current guidelines and individual therapeutic goals.

Q: Is Levosimendan safe in pregnancy or breastfeeding?

Safety data for Levosimendan during pregnancy and lactation are limited. Because potential risks cannot be ruled out, the drug is generally avoided unless the expected benefit justifies the potential hazard to the fetus or infant. Consultation with a specialist is essential.

Q: How do I order Levosimendan Waymade from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Q: How does Levosimendan compare with other inotropic agents?

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without markedly raising intracellular calcium, which may reduce the risk of calcium‑overload injury. Its combined vasodilatory effect can lower after‑load, whereas many other inotropes primarily raise heart rate and myocardial oxygen consumption.

Q: What are the storage and handling requirements for Levosimendan Waymade?

Levosimendan Waymade should be stored at ambient temperature, protected from moisture and light, and kept in its original packaging until use. Do not freeze the product, and ensure that any reconstituted solution is used within the time frame specified in the product label.

Q: How is Levosimendan administered?

Levosimendan is given as an intravenous infusion, usually initiated with a loading dose followed by a continuous maintenance infusion. Administration is performed under close clinical monitoring, with vital signs and cardiac rhythm observed throughout the infusion period.

Q: What are the most serious risks associated with Levosimendan?

The most serious adverse events include severe hypotension, ventricular arrhythmias, and anaphylactic reactions. These can be life‑threatening and require immediate medical intervention, such as vasopressor support, anti‑arrhythmic therapy, or emergency treatment of allergic symptoms.

Q: Who should not use Levosimendan?

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, severe hypotension, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment, and it should be avoided in pregnant or breastfeeding women unless absolutely necessary.

Levosimendan, the active ingredient in Levosimendan Waymade, is a calcium sensitizer presented as an intravenous solution for intravenous use. It is employed to improve cardiac contractility in patients with acute decompensated heart failure, helping to stabilize hemodynamics without markedly raising intracellular calcium levels. It is indicated for intravenous infusion in intensive care settings under physician supervision.

GNH India supplies Levosimendan Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Manufacturer / TM Owner

Waymade B.V.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of heart failure syndromes where enhanced cardiac contractility is required.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.
Low‑output syndrome after cardiac surgery: supports hemodynamics during postoperative recovery.
Severe systolic heart failure awaiting transplantation: stabilizes patients as a bridge to definitive therapy.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting myocardial contractile force without a rise in intracellular calcium concentration. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load. The combined inotropic and vasodilatory actions improve cardiac output while limiting myocardial oxygen consumption. These effects are dose‑dependent and are achieved during a short intravenous infusion lasting several hours.

Side Effects

Levosimendan may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Hypotension: drop in blood pressure, especially during initial infusion.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate.

Serious or Rare Side Effects

Severe hypotension: marked blood pressure fall requiring intervention.
Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Anaphylactic reaction: rare allergic response with airway compromise.

Precautions & Warnings

When using Levosimendan, clinicians should observe several precautionary measures to ensure patient safety.

Monitor blood pressure: watch for hypotension during and after infusion.
Observe cardiac rhythm: continuous ECG monitoring for arrhythmias.
Assess renal function: adjust use in patients with severe renal impairment.
Evaluate hepatic status: use cautiously in significant liver disease.
Avoid in severe hypotension: contraindicated when systolic BP <90 mmHg.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Levosimendan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Other vasodilators (e.g., nitroglycerin): may cause profound hypotension.
Potassium channel blockers (e.g., sulfonylureas): may diminish Levosimendan’s effect.
Strong CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.

Moderate Interactions (Monitor Closely)

Diuretics: may affect electrolyte balance and blood pressure.
ACE inhibitors or ARBs: additive blood‑pressure lowering effect.
Anticoagulants: monitor for increased bleeding risk.

Frequently Asked Questions